 BioXcel uses a proprietary AI program to screen for ways to repurpose old drugs and screen for useful biomarkers that can allow for faster, safer, and cheaper drug development. BioXcels lead asset BXCL501 is targeting a broad swath of agitation-related indications that could be very lucrative for the company. 